Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Clinical Trial Shows Pycnogenol® Significantly Relieves Lipedema Symptoms and Improves Quality of Life in Women

This image opens in the lightbox

News provided by

Horphag Research (USA) Inc.

09 Dec, 2025, 14:00 GMT

Share this article

Share toX

Share this article

Share toX

With no approved treatments for lipedema, this study highlights a promising natural option for symptom relief.

GENEVA, Dec. 9, 2025 /PRNewswire/ -- A newly published clinical study in Cureus Journal of Medical Science shows that Pycnogenol®, a natural plant extract from the bark of the French maritime pine tree, can significantly relieve the symptoms of lipedema, reduce body fat and improve self-esteem associated with the condition.

This image opens in the lightbox
Women taking Pycnogenol® saw a 29% reduction in symptoms by day 60, while symptoms in the placebo group continued to worsen.

Lipedema is a chronic and often misunderstood condition that affects about 400 million women globally. It causes an abnormal and painful buildup of fat, most often in the legs, hips and buttocks. It is frequently mistaken for obesity or lymphedema, often delaying diagnosis and leaving many women without effective treatment options.

About the Study

The double-blind, placebo-controlled study included 100 women between the ages of 18 and 40 diagnosed with lipedema and aimed to evaluate the effectiveness of Pycnogenol® in managing the condition. Participants were monitored over a 60-day period, with half receiving Pycnogenol® (50 mg, three times daily) and half receiving a placebo.

Researchers evaluated quality of life, body composition and symptom severity at the start, midpoint and conclusion of the study. Symptom severity was assessed using the validated QuASiL scale. The evaluation included sensitivity, bruising, pressure, burning, cramps, heavy legs, swelling and itchiness.

Key Findings

  • 29% reduction in symptoms by day 60 among women taking Pycnogenol®, while symptoms in the placebo group continued to worsen.
  • Pycnogenol® provided significant relief across all reported symptoms, with important improvements seen in the most common problems of lipedema: swelling of the legs, heavy legs, tenderness and bruising.
  • Participants experienced an 8% reduction in body fat compared to the placebo group over just 60 days of Pycnogenol® supplementation.
  • Women taking Pycnogenol® reported an improvement in satisfaction with leg appearance, as well as quality of life.
  • No adverse effects reported, supporting Pycnogenol®'s strong safety profile as a natural, non-invasive management option.

Why this Matters for Women's Health

Lipedema disproportionately affects women, with an estimated 11% to 39% experiencing symptoms ranging from tenderness and easy bruising to a heavy, aching sensation in the legs. Because it often develops or worsens during hormonal changes like puberty, pregnancy or menopause, it can have lifelong consequences for physical and emotional health.

Despite its prevalence, there are currently no approved medications for the treatment of lipedema, and no widely accepted medical standard of care. Most women rely on symptom-management strategies such as compression therapy, manual lymphatic drainage, physical therapy and lifestyle adjustments, which can help but do not address the underlying condition.

Pycnogenol®'s benefits to Lipedema stem from its antioxidant and anti-inflammatory properties, which help strengthen blood vessel walls, improve microcirculation and support lymphatic flow. These effects are particularly relevant for lipedema, where impaired circulation contributes to chronic swelling and tissue discomfort.

"The lack of validated, accessible treatment options for women with lipedema often leaves them searching for alternatives that can meaningfully improve daily comfort and mobility," says renowned natural physician and author, Dr. Fred Pescatore. "What makes these findings important is that Pycnogenol® demonstrated measurable improvements in symptoms including pain and tenderness relief, body composition and emotional well-being. Patients with lipedema now have a safe, natural option that may help fill a long-standing treatment gap."

A Step Toward Better Understanding and Management

The study, conducted at a vascular health clinic in Vitória, Brazil, was led by Dr. Brenno Augusto Seabra de Mello Netto. It represents one of the first clinical trials to evaluate a plant-based compound for managing lipedema symptoms.

To review clinical research and additional information on Pycnogenol®, visit www.pycnogenol.com. Pycnogenol® is available in more than 1,000 dietary supplements and health products worldwide. 

About Pycnogenol® 

Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and phenolic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 40 years and has more than 450 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol® is available in more than 1,000 dietary supplements and health products worldwide. For more information, visit www.pycnogenol.com.

About Horphag Research

Horphag Research is the exclusive worldwide distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract. Pycnogenol® is a registered trademark of Horphag Research. For its patented ingredient, Pycnogenol®, Horphag Research has been awarded the Frost & Sullivan Excellence in Research Award, Nutraceutical Business & Technology Safety & Quality Award, SupplySide West Scientific Excellence Award and The American Botanical Council's Tyler Research Award. Horphag Research has the exclusive rights to market and sell Pycnogenol® worldwide and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement.

Photo - https://mma.prnewswire.com/media/2840876/Lipedema_Study_Press_Release___FINAL___Illustration_chart_b.jpg
Logo - https://mma.prnewswire.com/media/478894/Pycnogenol_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.